Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | PHGDH | O43175 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1460281 | 0.97 | CYP1A2 (0.33) | TDP1CYP1A2HRH4PHGDHMGLL | |
| SCHEMBL4831157 | 0.93 | TDP1 (0.35) | TDP1CYP1A2PHGDHMGLLKDM4E | |
| SCHEMBL10780186 | 0.91 | LMNA (0.38) | TDP1CYP1A2KDM4E | |
| SCHEMBL15217805 | 0.89 | CYP1A2 (0.40) | TDP1CYP1A2PHGDHMGLLKDM4E | |
| SCHEMBL863155 | 0.81 | TDP1 (0.40) | TDP1CYP1A2HRH4PHGDHMGLL | |
| SCHEMBL22228575 | 0.81 | TDP1 (0.40) | TDP1CYP1A2HRH4PHGDHMGLL | |
| SCHEMBL14377635 | 0.81 | TDP1 (0.40) | TDP1CYP1A2HRH4PHGDHMGLL | |
| SCHEMBL2778576 | 0.80 | — | — | |
| SCHEMBL20116788 | 0.80 | KDM4E (0.33) | TDP1KDM4E | |
| SCHEMBL17771605 | 0.77 | LMNA (0.39) | TDP1CYP1A2HRH4PHGDHMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0001290-A1 | Substituted 2,3-dihydrobenz-(d)-isothiazole-1,1-dioxides and 2,3-dihydronaphtho-(1,8-de)-1,2-thiazine-1,1-dioxides | POLAROID CORPORATION (US) | 1979-04-04 | — | — | EP | claimed |
| EP-4327886-A2 | PYRIMIDO- PYRIDAZINONE COMPOUNDS AND USE THEREOF | Libertas Bio, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3672958-A1 | ANNULATED GLYCOSIDASE INHIBITORS | Asceneuron SA (CH) | 2020-07-01 | — | — | EP | disclosed |
| EP-3672959-A1 | LINEAR GLYCOSIDASE INHIBITORS | Asceneuron SA (CH) | 2020-07-01 | — | — | EP | disclosed |
| WO-2019037860-A1 | LINEAR GLYCOSIDASE INHIBITORS | Asceneuron S.A. (CH) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019037861-A1 | ANNULATED GLYCOSIDASE INHIBITORS | Asceneuron S.A. (CH) | 2019-02-28 | — | — | WO | disclosed |
| EP-3419976-A1 | ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES | Asceneuron SA (CH) | 2019-01-02 | — | — | EP | disclosed |
| EP-3419972-A1 | GLYCOSIDASE INHIBITORS | Asceneuron SA (CH) | 2019-01-02 | — | — | EP | disclosed |
| EP-3419971-A1 | GLYCOSIDASE INHIBITORS | Asceneuron SA (CH) | 2019-01-02 | — | — | EP | disclosed |
| WO-2018153508-A2 | SULFOXIMINE GLYCOSIDASE INHIBITORS | Asceneuron S.A. (CH) | 2018-08-30 | — | — | WO | disclosed |
| WO-2018153507-A1 | SUBSTITUTED DIHYDROBENZOFURAN GLYCOSIDASE INHIBITORS | Asceneuron S.A. (CH) | 2018-08-30 | — | — | WO | disclosed |
| WO-2017144639-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON S. A. (CH) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017144637-A1 | ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES | ASCENEURON S. A. (CH) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017144633-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON S. A. (CH) | 2017-08-31 | — | — | WO | disclosed |
| EP-3186243-A1 | GLYCOSIDASE INHIBITORS | Asceneuron SA (CH) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016030443-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2016-03-03 | — | — | WO | disclosed |
| US-20040171614-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171614-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | TDP1 1830/4885CYP1A2 1966/4885HRH4 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.